Literature DB >> 4159100

Possible induction of antinuclear antibodies by isoniazid.

A Cannat, M Seligmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 4159100     DOI： 10.1016/s0140-6736(66)90704-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  Antinuclear antibodies in patients on anticonvulsant therapy.

Authors:  D Alarcón-Segovia; E Fishbein; P A Reyes; H Díes; S Shwadsky
Journal:  Clin Exp Immunol       Date:  1972-09       Impact factor: 4.330

2.  Antinuclear factor in rapid and slow acetylator patients treated with isoniazid.

Authors:  D A Evans; M F Bullen; J Houston; C A Hopkins; J M Vetters
Journal:  J Med Genet       Date:  1972-03       Impact factor: 6.318

3.  Induction by isoniazid and hydrallazine of antinuclear factors in mice.

Authors:  A Cannat; M Seligmann
Journal:  Clin Exp Immunol       Date:  1968-01       Impact factor: 4.330

4.  Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid.

Authors:  D Alarcón-Segovia; E Fishbein; V M Betancourt
Journal:  Clin Exp Immunol       Date:  1969-10       Impact factor: 4.330

5.  Drug-induced lupus syndromes.

Authors: 
Journal:  Br Med J       Date:  1970-04-25

6.  Natural antibodies to procaine amide.

Authors:  A S Russell; M Ziff
Journal:  Clin Exp Immunol       Date:  1968-11       Impact factor: 4.330

7.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 8.  Drug-induced lupus.

Authors:  E J Price; P J Venables
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

9.  Effect of 1,1-dimethylhydrazine on lymphoproliferation and interleukin 2 immunoregulatory function.

Authors:  R M Bauer; M J Tarr; R G Olsen
Journal:  Arch Environ Contam Toxicol       Date:  1990 Jan-Feb       Impact factor: 2.804

10.  Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections.

Authors:  D A Isenberg; P Maddison; G Swana; R P Skinner; M Swana; M Jones; I Addison; C Dudeney; S Shall; A el Roiey
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.